Creagan E T, Fleming T R, Edmonson J H, Pairolero P C
Cancer. 1979 Nov;44(5):1908-12. doi: 10.1002/1097-0142(197911)44:5<1908::aid-cncr2820440553>3.0.co;2-2.
Analysis was made of 112 patients who underwent resection of metastatic pulmonary noldules for nonosteogenic sarcoma at the Mayo Clinic from 1950--76. The 5-year post-thoracotomy survival was 29% with a median survival of 18 months. There has been no substantial change between 1950 and 1976 in post-thoracotomy survival among all patients who received this operation here. Prognosis was especially grim (p less than 0.01) for patients with pre-thoracotomy disease-free intervals of less than 12 months, and for those experiencing extrathoracic recurrences vs. further pulmonary recurrent tumor (p = .01) following thoracotomy. The following discriminants were not significantly associated with postthoracotomy survival: age, sex, histology, number of lesions fully excised, or site of lung lesions. We conclude that the therapeutic value of thoracotomy in the treatment of metastatic nonosteogenic sarcomas has not changed here during the past quarter of a century. Whether the recent more common use of thoracotomy in metastatic disease of this type is therapeutically worthwhile cannot be clearly determined from the data available.
对1950年至1976年间在梅奥诊所因非骨肉瘤接受转移性肺结节切除术的112例患者进行了分析。开胸术后5年生存率为29%，中位生存期为18个月。1950年至1976年间，在此接受该手术的所有患者的开胸术后生存率没有实质性变化。开胸术前无病间期少于12个月的患者，以及开胸术后出现胸外复发与肺部再次出现肿瘤（p = 0.01）的患者，预后尤其严峻（p < 0.01）。以下因素与开胸术后生存率无显著相关性：年龄、性别、组织学类型、完全切除的病灶数量或肺部病灶部位。我们得出结论，在过去四分之一世纪里，开胸手术在转移性非骨肉瘤治疗中的价值在此未发生变化。根据现有数据尚无法明确确定近期在这类转移性疾病中更常用的开胸手术在治疗上是否值得。
